Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06785415 · ClinicalTrials.gov registry record · Phase 1

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

A Phase 1 study of Recurrent Multiple Myeloma, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 1
Development phase
37
Enrollment target
1
Study location

NCT06785415 is a Phase 1 study of Recurrent Multiple Myeloma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 37 participants, above the 29-participant average among 15 other Recurrent Multiple Myeloma trials with a reported enrollment target (28% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06785415, a Phase 1 study of Recurrent Multiple Myeloma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 1
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Elotuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving iberdomide in combination with daratumumab, elotuzumab, and dexamethasone may be safe, tolerable and/or effective in patients with relapsed multiple myeloma.

Conditions Studied

Recurrent Multiple Myeloma

Interventions

  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • PROCEDURE Bone Scan
  • PROCEDURE Chest Radiography

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2025-03-18
Est. Completion 2031-04-01
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06785415

The ClinicalTrials.gov registry entry for NCT06785415 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 29-participant average among 15 other Recurrent Multiple Myeloma trials with a reported enrollment target (28% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Bone Marrow Aspiration is the first listed.

NCT06785415 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06785415 about?

NCT06785415 is a clinical study titled "Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma". This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide...

What is the current status of trial NCT06785415?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-03-18. Estimated completion is 2031-04-01.

What conditions does trial NCT06785415 study?

This clinical trial studies the following conditions: Recurrent Multiple Myeloma.

What interventions are being tested in trial NCT06785415?

The interventions under investigation include: Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Bone Scan (PROCEDURE), Chest Radiography (PROCEDURE).

Who is sponsoring clinical trial NCT06785415?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06785415 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Multiple Myeloma

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.